Early Phase 1 Trial, 5G Robotic Hepatectomy, 10 Patients
Summary
This ClinicalTrials.gov record documents a prospective, single-arm Early Phase 1 study (NCT07551063) evaluating 5G-based remote robotic hepatectomy using the Chinese Toumai™ robotic system for hepatic echinococcosis in high-altitude regions. Expert surgeons at West China Hospital in Chengdu will perform procedures on 10 patients located at West China Hospital Tibet Hospital in Lhasa (3,650m altitude). The primary endpoints are surgical success rate and perioperative safety.
“This prospective, single-arm study aims to evaluate the feasibility and safety of performing remote robotic hepatectomy using the Chinese Toumai™ robotic system over a 5G network.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov record registers the first formal study of a novel 5G-enabled telerobotic hepatectomy technique using the Chinese Toumai™ robotic system for hepatic echinococcosis, a parasitic disease endemic to high-altitude regions such as Xizang (Tibet). The trial will enroll 10 patients at West China Hospital Tibet Hospital in Lhasa, with remote surgery performed by expert surgeons at West China Hospital in Chengdu, and will assess surgical success rates and perioperative safety.
Healthcare institutions in high-altitude regions where hepatic echinococcosis is endemic may eventually reference these results as early feasibility evidence for remote expert surgical support via 5G. Any clinical adoption of similar telerobotic models would require independent ethics and regulatory review beyond this registry entry.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
5G Remote Robotic Surgery for Hepatic Echinococcosis in High-Altitude Region
Early Phase 1 NCT07551063 Kind: EARLY_PHASE1 Apr 24, 2026
Abstract
Hepatic echinococcosis (HE) is a serious endemic parasitic disease in high-altitude regions like Xizang. Radical hepatectomy is the primary curative treatment, but expert resources are often concentrated in large medical centers. This prospective, single-arm study aims to evaluate the feasibility and safety of performing remote robotic hepatectomy using the Chinese Toumai™ robotic system over a 5G network. Ten patients in West China Hospital Tibet Hospital, Sichuan University (Lhasa, 3650m altitude) will undergo surgery performed by expert surgeons at West China Hospital (Chengdu). The primary focus is the surgical success rate and perioperative safety.
Conditions: Hepatic Echinococcosis
Interventions: 5G-based Telerobotic Hepatectomy
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.